アンファスター・ファーマは,同年比の収益が安定したにもかかわらず,BAQSIMIの成長と新製品により,2025年第3四半期における収益推定額を191.8Mドルの収益と0.93ドルのEPSで上回った. Amphastar Pharma beat earnings estimates in Q3 2025 with $191.8M revenue and $0.93 EPS, driven by BAQSIMI growth and new products, despite flat year-over-year revenue.

アンファスター製薬は2025年第3四半期の売上高で1,918万ドル,株当たり0.93ドルの調整利益を報告し,同年比の売上高が安定したにもかかわらず,予想を上回った. Amphastar Pharmaceuticals reported $191.8 million in third-quarter 2025 revenue and adjusted earnings of $0.93 per share, exceeding expectations despite flat year-over-year revenue. BAQSIVI 売上高が14%上昇し,FDAの鉄の吸入を含んだ新製品が開始された. Growth was driven by a 14% increase in BAQSIMI® sales and new product launches, including FDA-approved iron sucrose injection. 同社は,世界的なBAQSMIMI 分布への移行を完了し,前第三者収入を廃止した. The company completed its transition to global BAQSIMI® distribution, eliminating prior third-party revenue. 一部の製品は競争と価格の圧力により減少したが,戦略的パイプライン投資及び内閣製造は,成果を支えた. While some products faced declines due to competition and pricing pressures, strategic pipeline investments and in-house manufacturing supported performance. 操作の余白は減少し,近期成長の予測は控えたままである. Operating margins declined, and near-term growth forecasts remain modest.